ACT Stock Overview
AlzChem Group AG develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally.
AlzChem Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€23.90|
|52 Week High||€26.20|
|52 Week Low||€19.40|
|1 Month Change||8.64%|
|3 Month Change||-4.40%|
|1 Year Change||18.91%|
|3 Year Change||0.42%|
|5 Year Change||n/a|
|Change since IPO||-11.12%|
Recent News & Updates
AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
AlzChem Group AG ( ETR:ACT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...
Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Today we will run through one way of estimating the intrinsic value of AlzChem Group AG ( ETR:ACT ) by estimating the...
|ACT||DE Chemicals||DE Market|
Return vs Industry: ACT exceeded the German Chemicals industry which returned 3.6% over the past year.
Return vs Market: ACT exceeded the German Market which returned 15.3% over the past year.
|ACT Average Weekly Movement||2.9%|
|Chemicals Industry Average Movement||4.0%|
|Market Average Movement||4.8%|
|10% most volatile stocks in DE Market||8.9%|
|10% least volatile stocks in DE Market||2.4%|
Stable Share Price: ACT is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ACT's weekly volatility (3%) has been stable over the past year.
About the Company
AlzChem Group AG develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand.
AlzChem Group Fundamentals Summary
|ACT fundamental statistics|
Is ACT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACT income statement (TTM)|
|Cost of Revenue||€160.66m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Feb 24, 2022
|Earnings per share (EPS)||2.62|
|Net Profit Margin||6.34%|
How did ACT perform over the long term?See historical performance and comparison
3.2%Current Dividend Yield
Is AlzChem Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ACT (€23.9) is trading below our estimate of fair value (€92.71)
Significantly Below Fair Value: ACT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ACT is good value based on its PE Ratio (9.1x) compared to the German Chemicals industry average (11.9x).
PE vs Market: ACT is good value based on its PE Ratio (9.1x) compared to the German market (21.3x).
Price to Earnings Growth Ratio
PEG Ratio: ACT is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: ACT is overvalued based on its PB Ratio (3x) compared to the DE Chemicals industry average (2.2x).
How is AlzChem Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACT's forecast earnings growth (8.3% per year) is above the savings rate (-0.01%).
Earnings vs Market: ACT's earnings (8.3% per year) are forecast to grow slower than the German market (12.2% per year).
High Growth Earnings: ACT's earnings are forecast to grow, but not significantly.
Revenue vs Market: ACT's revenue (5.1% per year) is forecast to grow slower than the German market (5.9% per year).
High Growth Revenue: ACT's revenue (5.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ACT's Return on Equity is forecast to be high in 3 years time (22.4%)
How has AlzChem Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ACT has a high level of non-cash earnings.
Growing Profit Margin: ACT's current net profit margins (6.3%) are higher than last year (4.3%).
Past Earnings Growth Analysis
Earnings Trend: ACT's earnings have grown by 3.9% per year over the past 5 years.
Accelerating Growth: ACT's earnings growth over the past year (66.5%) exceeds its 5-year average (3.9% per year).
Earnings vs Industry: ACT earnings growth over the past year (66.5%) exceeded the Chemicals industry 54.1%.
Return on Equity
High ROE: ACT's Return on Equity (32.9%) is considered high.
How is AlzChem Group's financial position?
Financial Position Analysis
Short Term Liabilities: ACT's short term assets (€159.2M) exceed its short term liabilities (€82.6M).
Long Term Liabilities: ACT's short term assets (€159.2M) do not cover its long term liabilities (€217.3M).
Debt to Equity History and Analysis
Debt Level: ACT is debt free.
Reducing Debt: ACT has no debt compared to 5 years ago when its debt to equity ratio was 74.8%.
Debt Coverage: ACT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ACT has no debt, therefore coverage of interest payments is not a concern.
What is AlzChem Group current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ACT's dividend (3.22%) is higher than the bottom 25% of dividend payers in the German market (1%).
High Dividend: ACT's dividend (3.22%) is low compared to the top 25% of dividend payers in the German market (3.27%).
Stability and Growth of Payments
Stable Dividend: ACT has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: ACT has only been paying a dividend for 4 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (29.4%), ACT's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ACT's dividends in 3 years are forecast to be well covered by earnings (30% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andreas Niedermaier (52 yo)
Mr. Andreas Niedermaier has been Chairman of Executive Board & Chief Executive Officer at AlzChem Group AG since July 01, 2019 and has been its Member of Management Board since October 20, 2011. He served...
CEO Compensation Analysis
Compensation vs Market: Andreas's total compensation ($USD935.84K) is above average for companies of similar size in the German market ($USD498.59K).
Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.
Experienced Management: ACT's management team is considered experienced (2.3 years average tenure).
Experienced Board: ACT's board of directors are seasoned and experienced ( 12.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
AlzChem Group AG's employee growth, exchange listings and data sources
- Name: AlzChem Group AG
- Ticker: ACT
- Exchange: XTRA
- Founded: 1908
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: €242.904m
- Shares outstanding: 10.16m
- Website: https://www.alzchem.com
Number of Employees
- AlzChem Group AG
- Dr.-Albert-Frank-Strasse 32
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/27 18:48|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.